p16基因表达在卵巢癌分化程度诊断及化疗疗效判断中的意义

目的:研究p16基因的表达在卵巢癌的生物学特性的诊断以及化疗预后的判断中的意义。方法:采用免疫组化检测78例上皮性卵巢癌患者p16的表达,其中52例予以4～6个疗程以铂类为主的TP联合化疗,26例予以4～6个疗程的拓扑替康单药治疗,分析p16的表达与癌细胞多种生物学特性之间的关系以及与化疗疗效之间的关系。结果:52.6%的卵巢癌p16阴性表达,并且与癌细胞的分化程度呈明显相关性。采用TP方案的铂类联合化疗,其疗效与癌细胞p16表达无相关性(P>0.05),而采用拓扑替康单药化疗,p16阳性表达的患者其疗效明显好于p16阴性组的疗效(P<0.05)。结论:卵巢癌中高频率的p16基因活性缺失与癌细胞的分化程度密切相关,检测p16基因表达有可能作为癌细胞分化及恶性度的判断指标。此外,p16基因表达可能影响肿瘤细胞对部分化疗药物的敏感性,这对于指导临床肿瘤化疗方案的选择具有重要的参考意义,并可能用于患者化疗预后的判断。

Significance of p16 gene expression in the differentiation diagnosis and chemosensitivity judgment of ovarian carcinoma

Objective To investigate the relationship between p16 gene expression and the biological characte-ristics and the chemosensitivity of ovarian carcinoma. Methods p16 gene expression in 78 resected ovarian carcinoma specimens was determined by immunohistochemistry. Of 78 cases of overian carcinoma, 52 received 4 to 6 courses of platinum-based TP combined chemotherapy and the other 26 received 4 to 6 courses of topotecan chemotherapy. The correlations between p16 gene expression and the biological characteristics and the chemotheraputic effect were analyzed. Results p16 gene showed negative expression in 52.6% of ovarian carcinomas, which was significantly correlated to the differentiation of the cancer cells. No correlation was observed between the efficacy of the platinum-based TP combined chemotherapy and p16 expression (P>0.05). However, the efficacy of the topotecan chemotherapy was closely related to p16 expression (P<0.05). Conclusions The high frequency of p16 inactivation(loss) in ovarian carcinomas is associated with the differentiation of cancer cells and is also related to the chemosensitivity of some chemotherapeutic agents, which may be helpful for the clinical diagnosis and the prognostic judgement in ovarian carcinoma.